Literature DB >> 22274832

Treating Graves' orbitopathy: where are we?

Maria Laura Tanda, Eliana Piantanida, Luigi Bartalena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22274832     DOI： 10.1007/s12020-012-9607-1

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  15 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

Review 2.  The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.

Authors:  Luigi Bartalena
Journal:  J Clin Endocrinol Metab       Date:  2010-12-29       Impact factor: 5.958

3.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

Review 4.  Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Authors:  L Bartalena; C Marcocci; A Lai; M L Tanda
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

5.  What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?

Authors:  Luigi Bartalena
Journal:  Clin Endocrinol (Oxf)       Date:  2010-02-10       Impact factor: 3.478

Review 6.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

7.  Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy.

Authors:  Chu Zhang; Xianfeng Zhang; Lizhen Ma; Fengying Peng; Jiao Huang; Hui Han
Journal:  Endocrine       Date:  2012-01-12       Impact factor: 3.633

Review 8.  Dose of intravenous steroids and therapy outcome in Graves' orbitopathy.

Authors:  S Zang; K A Ponto; S Pitz; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2011-12       Impact factor: 4.256

Review 9.  Pathogenesis of Graves' orbitopathy: a 2010 update.

Authors:  T J Smith
Journal:  J Endocrinol Invest       Date:  2010-06       Impact factor: 4.256

10.  Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.

Authors:  Mariacarla Moleti; Filiberto Mattina; Ignazio Salamone; Maria Antonia Violi; Carmelo Nucera; Sergio Baldari; Maria Grazia Lo Schiavo; Concetto Regalbuto; Francesco Trimarchi; Francesco Vermiglio
Journal:  Thyroid       Date:  2003-07       Impact factor: 6.568
View more
  2 in total

1.  Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.

Authors:  K A Ponto; T Diana; H Binder; N Matheis; S Pitz; N Pfeiffer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

2.  Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy.

Authors:  Gustavo Savino; Erika Mandarà; Mariangela Gari; Remo Battendieri; Salvatore Maria Corsello; Alfredo Pontecorvi
Journal:  Endocrine       Date:  2014-06-01       Impact factor: 3.633
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.